Introduction: Cerebral palsy is today the most common pathology leading to a motor disability in children. Physiotherapy has always been, and still is, an essential management for the evolution of the child. Therefore, in order to maximize its effects, botulinum toxin injections may be proposed with the aim of reducing spasticity and thus improving global motor function.Objective: The aim of this systematic review is to assess the evolution of spasticity and global motor function following physiotherapy management, with or without injections of type A botulinum toxin in children with cerebral palsy.Method: To conduct this review, 7 studies were included. These were found in three different databases (PubMed, Pedro, Cochrane). All of these a...
Contains fulltext : 50246.pdf (publisher's version ) (Closed access)OBJECTIVE: To ...
IntroductionOur objective was to show the effects of botulinum toxin injections (BT) on function and...
Objectives: To examine the efficacy and safety of intramuscular botulinum toxin A (BoNT-A) to reduce...
Cerebral palsy is the most common cause of motor impairment in children, affecting 2.08 to 3.60 chil...
Cerebral palsy (CP) affects around every one in 500 children born. It isn’t a particular illness or ...
La paralysie cérébrale, cause la plus fréquente des déficiences motrices de l’enfant, affecte entre ...
BACKGROUND: To assess treatment effect of lower limb botulinum toxin type A (BTX-A) in combination w...
Introduction: Cerebral palsy (CP) is a group of disorders that affect muscle movement, tone and coor...
INTRODUCTION: Cerebral palsy is the most common cause of physical disability in children. Spasticity...
BACKGROUND: To assess treatment effect of lower limb botulinum toxin type A (BTX-A) in combination w...
International audienceBACKGROUND: Dystonia and spasticity are common symptoms in children with Cereb...
Background & objectives: Botulinum toxin is considered as an effective treatment for spasticity in c...
ObjectiveBotulinum toxin type A (BtA) injection in the therapeutic treatment of muscle hypertonicity...
Une étude clinique prospective a été réalisée afin d'évaluer l'efficacité desinjections intra-muscul...
Purpose The purpose of this review is to clarify the role of botulinum toxin serotype A (BTX-A) in t...
Contains fulltext : 50246.pdf (publisher's version ) (Closed access)OBJECTIVE: To ...
IntroductionOur objective was to show the effects of botulinum toxin injections (BT) on function and...
Objectives: To examine the efficacy and safety of intramuscular botulinum toxin A (BoNT-A) to reduce...
Cerebral palsy is the most common cause of motor impairment in children, affecting 2.08 to 3.60 chil...
Cerebral palsy (CP) affects around every one in 500 children born. It isn’t a particular illness or ...
La paralysie cérébrale, cause la plus fréquente des déficiences motrices de l’enfant, affecte entre ...
BACKGROUND: To assess treatment effect of lower limb botulinum toxin type A (BTX-A) in combination w...
Introduction: Cerebral palsy (CP) is a group of disorders that affect muscle movement, tone and coor...
INTRODUCTION: Cerebral palsy is the most common cause of physical disability in children. Spasticity...
BACKGROUND: To assess treatment effect of lower limb botulinum toxin type A (BTX-A) in combination w...
International audienceBACKGROUND: Dystonia and spasticity are common symptoms in children with Cereb...
Background & objectives: Botulinum toxin is considered as an effective treatment for spasticity in c...
ObjectiveBotulinum toxin type A (BtA) injection in the therapeutic treatment of muscle hypertonicity...
Une étude clinique prospective a été réalisée afin d'évaluer l'efficacité desinjections intra-muscul...
Purpose The purpose of this review is to clarify the role of botulinum toxin serotype A (BTX-A) in t...
Contains fulltext : 50246.pdf (publisher's version ) (Closed access)OBJECTIVE: To ...
IntroductionOur objective was to show the effects of botulinum toxin injections (BT) on function and...
Objectives: To examine the efficacy and safety of intramuscular botulinum toxin A (BoNT-A) to reduce...